Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update
July 22 2021 - 2:00AM
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a
clinical-stage biopharmaceutical company focused on respiratory
diseases, announces that it will report its financial results for
the three and six months ended June 30, 2021 on Thursday, August 5,
2021 and host an investment community conference call at 8:30 a.m.
EDT / 1:30 p.m. BST to discuss these financial results and provide
a corporate update.
To participate, please dial one of the following
numbers and reference conference ID 8333487:
- +1-888-317-6003 for callers in the
United States
- +1-412-317-6061 for international
callers
A live webcast will be available on the Events
and Presentations link on the Investors page of the Company’s
website, www.veronapharma.com, and the audio replay will be
available for 90 days.
For further information please contact:
Verona Pharma plc |
US Tel: +1-833-417-0262UK Tel: +44 (0)203 283 4200 |
Victoria Stewart, Director of Investor Relations and
Communications |
info@veronapharma.com |
|
|
Argot Partners(US Investor Enquiries) |
Tel: +1-212-600-1902verona@argotpartners.com |
Kimberly Minarovich / Michael Barron |
|
|
|
Optimum Strategic Communications(International
Media and European Investor Enquiries) |
Tel: +44 (0)203 950 9144verona@optimumcomms.com |
Mary Clark / Karl Hard / Elakiya Rangarajah |
|
About Verona Pharma
Verona Pharma is a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for the treatment of respiratory diseases with
significant unmet medical needs. If successfully developed and
approved, Verona Pharma’s product candidate, ensifentrine, has the
potential to be the first therapy for the treatment of respiratory
diseases that combines bronchodilator and anti-inflammatory
activities in one compound. The Company is evaluating nebulized
ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine
as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance
treatment. Two additional formulations of ensifentrine are in Phase
2 development for the treatment of COPD: dry powder inhaler (“DPI”)
and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has
potential applications in cystic fibrosis, asthma and other
respiratory diseases. For more information, please
visit www.veronapharma.com.
Verona Pharma (NASDAQ:VRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Verona Pharma (NASDAQ:VRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024